A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination with Chemotherapy for Resectable Pancreatic Cancer
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs Antineoplastics (Primary) ; VRT-106 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 07 Jan 2025 New trial record